Back to discover
Disease

Chronic Disease

Late-stage therapeutic developmentActively researchedRising momentum
92
Publications
15
Clinical trials
12
Related conditions
1
Related treatments
1
Related proteins
2025
Latest publication
Current focus
Therapeutic developmentInflammation & immunityDisease mechanisms & pathology
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this disease.

Neural Plasticity in Migraine Chronification.

Research2025-01-01The European journal of neuroscience

Microplastics and human health: unveiling the gut microbiome disruption and chronic disease risks.

Research2024-11-25Frontiers in cellular and infection microbiology

Inflammation unites diverse acute and chronic diseases.

Research2024-07-24European journal of clinical investigation

What's happening now

An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.

Executive briefingUpdating summary…Momentum: Moderate
Key developments
  • 3 regulatory approvals from EMA on record.
  • Active recent publication activity, including 1 notable finding.
  • 1 safety action from EMA issued.
  • 1 clinical trial with recent milestones.
  • 2 industry developments reported.
Major developments
Important regulatory approvalHigh impact
Bopediat is indicated in children from birth to less than 18 years of age for the treatment of oedema of cardiac or renal origin, oedema of hepatic origin, and hypertension in patients with chronic kidney disease.2026-05-29
Important regulatory approvalHigh impact
Asthma  Exdensur is indicated as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by blood eosinophil count in adults and adolescents 12 years and older who are inadequately controlled despite high dose inhaled corticosteroids (ICS) plus another asthma controller (see section 5.1). Chronic rhinosinusitis with nasal polyps (CRSwNP)  Exdensur is indicated as an add-on therapy with intranasal corticosteroids for the treatment of adult patients with severe CRSwNP for whom therapy with systemic corticosteroids and/or surgery do not provide adequate disease control.2026-02-12
Research Highlights3View
Clinical Milestones1View
Industry & Market2View
Regulatory Updates4View
  • 2026-05-29Approval — FurosemideBopediat is indicated in children from birth to less than 18 years of age for the treatment of oedema of cardiac or renal origin, oedema of hepatic origin, and hypertension in patients with chronic kidney disease.
  • 2026-04-14Market withdrawal — LusutrombopagMulpleo is indicated for the treatment of severe thrombocytopenia in adult patients with chronic liver disease undergoing invasive procedures
  • 2026-02-12Approval — DepemokimabAsthma  Exdensur is indicated as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by blood eosinophil count in adults and adolescents 12 years and older who are inadequately controlled despite high dose inhaled corticosteroids (ICS) plus another asthma controller (see section 5.1). Chronic rhinosinusitis with nasal polyps (CRSwNP)  Exdensur is indicated as an add-on therapy with intranasal corticosteroids for the treatment of adult patients with severe CRSwNP for whom therapy with systemic corticosteroids and/or surgery do not provide adequate disease control.
  • 2025-08-22Approval — NintedanibNintedanib Viatris is indicated in adults for the treatment of idiopathic pulmonary fibrosis (IPF). Nintedanib Viatris is also indicated in adults for the treatment of other chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype. Nintedanib Viatris is indicated in children and adolescents from 6 to 17 years old for the treatment of clinically significant, progressive fibrosing interstitial lung diseases (ILDs). Nintedanib Viatris is indicated in adults, adolescents and children aged 6 years and older for the treatment of systemic sclerosis associated interstitial lung disease (SSc-ILD).
Activity timeline10

Therapeutic landscape

Therapies with a regulatory footing for this condition, alongside the wider set of agents co-studied with it in the literature.

Approved & established therapies
Depemokimabapproved

Approval — Asthma  Exdensur is indicated as add-on maintenance treatment for severe asthma with… (2026)

Furosemideapproved

Approval — Bopediat is indicated in children from birth to less than 18 years of age for the treatme… (2026)

Nintedanibapproved

Approval — Nintedanib Viatris is indicated in adults for the treatment of idiopathic pulmonary fibro… (2025)

Apremilastapproved

Approval — Psoriatic arthritis Apremilast Accord, alone or in combination with Disease Modifying Ant… (2024)

Omalizumabapproved

Approval — Allergic asthma Omlyclo is indicated in adults, adolescents and children (6 to <12 yea… (2024)

Approval — Type 2 diabetes mellitus Dapagliflozin Viatris is indicated in adults and children aged 1… (2023)

Vadadustatapproved

Approval — Vafseo is indicated for the treatment of symptomatic anaemia associated with chronic kidn… (2023)

Research-associated treatments

Clinical trials

11 sponsors · 0 new · 0 completed in the last 12 months (net +0)

The current development programme across all trial phases.

Clinical programme
15
All trials
2
Active
3
Late-stage
6
Completed
Recently completed

Regulatory timeline

Drug regulatory events matched to this condition by indication — EMA.

First approvals
2026emaApprovalFurosemide· Bopediat is indicated in children from birth to less than 18 years of age for the treatment of oedema of cardiac or renal origin, oedema of hepatic origin, and hypertension in patients with chronic kidney disease. source ↗
2026emaApprovalDepemokimab· Asthma  Exdensur is indicated as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by blood eosinophil count in adults and adolescents 12 years and older who are inadequately controlled despite high dose inhaled corticosteroids (ICS) plus another asthma controller (see section 5.1). Chronic rhinosinusitis with nasal polyps (CRSwNP)  Exdensur is indicated as an add-on therapy with intranasal corticosteroids for the treatment of adult patients with severe CRSwNP for whom therapy with systemic corticosteroids and/or surgery do not provide adequate disease control. source ↗
2025emaApprovalNintedanib· Nintedanib Viatris is indicated in adults for the treatment of idiopathic pulmonary fibrosis (IPF). Nintedanib Viatris is also indicated in adults for the treatment of other chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype. Nintedanib Viatris is indicated in children and adolescents from 6 to 17 years old for the treatment of clinically significant, progressive fibrosing interstitial lung diseases (ILDs). Nintedanib Viatris is indicated in adults, adolescents and children aged 6 years and older for the treatment of systemic sclerosis associated interstitial lung disease (SSc-ILD). source ↗
2024emaApprovalOmalizumab· Allergic asthma Omlyclo is indicated in adults, adolescents and children (6 to <12 years of age).  Omlyclo treatment should only be considered for patients with convincing IgE (immunoglobulin E) mediated asthma (see section 4.2). Adults and adolescents (12 years of age and older) Omlyclo is indicated as add-on therapy to improve asthma control in patients with severe persistent allergic asthma who have a positive skin test or in vitro reactivity to a perennial aeroallergen and who have reduced lung function (FEV1 <80%) as well as frequent daytime symptoms or night-time awakenings and who have had multiple documented severe asthma exacerbations despite daily high-dose inhaled corticosteroids, plus a long-acting inhaled beta2-agonist. Children (6 to <12 years of age) Omlyclo is indicated as add-on therapy to improve asthma control in patients with severe persistent allergic asthma who have a positive skin test or in vitro reactivity to a perennial aeroallergen and frequent daytime symptoms or night-time awakenings and who have had multiple documented severe asthma exacerbations despite daily high-dose inhaled corticosteroids, plus a long-acting inhaled beta2-agonist. Chronic rhinosinusitis with nasal polyps (CRSwNP) Omlyclo is indicated as an add-on therapy with intranasal corticosteroids (INC) for the treatment of adults (18 years and above) with severe CRSwNP for whom therapy with INC does not provide adequate disease control. Chronic spontaneous urticaria (CSU) Omlyclo is indicated as add-on therapy for the treatment of chronic spontaneous urticaria in adult and adolescent (12 years and above) patients with inadequate response to H1 antihistamine treatment. source ↗
2024emaApprovalNintedanib· Nintedanib Accord is indicated in adults for the treatment of idiopathic pulmonary fibrosis (IPF). Nintedanib Accord is also indicated in adults for the treatment of other chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype (see section 5.1). Nintedanib Accord is indicated in adults for the treatment of systemic sclerosis associated interstitial lung disease (SSc-ILD). Nintedanib Accord is indicated in adults for the treatment of idiopathic pulmonary fibrosis (IPF). Nintedanib Accord is also indicated in adults for the treatment of other chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype. Nintedanib Accord is indicated in children and adolescents from 6 to 17 years old for the treatment of clinically significant, progressive fibrosing interstitial lung diseases (ILDs). Nintedanib Accord is indicated in adults, adolescents and children aged 6 years and older for the treatment of systemic sclerosis associated interstitial lung disease (SSc-ILD). source ↗
2024emaApprovalApremilast· Psoriatic arthritis Apremilast Accord, alone or in combination with Disease Modifying Antirheumatic Drugs (DMARDs), is indicated for the treatment of active psoriatic arthritis (PsA) in adult patients who have had an inadequate response or who have been intolerant to a prior DMARD therapy (see section 5.1).Psoriasis Apremilast Accord is indicated for the treatment of moderate to severe chronic plaque psoriasis in adult patients who failed to respond to or who have a contraindication to, or are intolerant to other systemic therapy including cyclosporine, methotrexate or psoralen and ultraviolet-A light (PUVA).Behçet’s disease Apremilast Accord is indicated for the treatment of adult patients with oral ulcers associated with Behçet’s disease (BD) who are candidates for systemic therapy. source ↗
2023emaApprovalVadadustat· Vafseo is indicated for the treatment of symptomatic anaemia associated with chronic kidney disease (CKD) in adults on chronic maintenance dialysis. source ↗
2023emaApprovalDapagliflozin· Type 2 diabetes mellitus Dapagliflozin Viatris is indicated in adults and children aged 10 years and above for the treatment of insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise - as monotherapy when metformin is considered inappropriate due to intolerance. - in addition to other medicinal products for the treatment of type 2 diabetes. For study results with respect to combination of therapies, effects on glycaemic control, cardiovascular and renal events, and the populations studied, see sections 4.4, 4.5 and 5.1. Heart failure Dapagliflozin Viatris is indicated in adults for the treatment of symptomatic chronic heart failure with reduced ejection fraction. Chronic kidney disease Dapagliflozin Viatris is indicated in adults for the treatment of chronic kidney disease. source ↗
Safety updates
2026emaMarket withdrawalLusutrombopag· Mulpleo is indicated for the treatment of severe thrombocytopenia in adult patients with chronic liver disease undergoing invasive procedures source ↗

European Medicines Agency (CC BY 4.0). Events are matched to this condition by drug indication text — approvals/updates for drugs indicated for it, not disease-specific acts.

Research activity

92 papers

Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.

Publications over time
20142025
Most influential
Recent publications
Major themes8
  • Inflammation3
  • Antioxidants2
  • Brain Injuries, Traumatic2
  • Cardiology2
  • Communicable Diseases2
  • Cost of Illness2
  • Epidemiologic Research Design2
  • Heart Failure2
Leading journals6
  • European heart journal7
  • Frontiers in immunology7
  • International journal of molecular sciences5
  • The Journal of neuroscience : the official journal of the Society for Neuroscience4
  • European journal of epidemiology3
  • The New England journal of medicine3
Leading researchers8
  • Jaarsma T3
  • Stricker BH3
  • Uitterlinden AG3
  • Adamo M2
  • Alomar SY2
  • Alwasel SH2
  • Bjermer L2
  • Čelutkienė J2
Affiliations (unnormalised)6
  • Aarhus University Hospital3
  • Brigham and Women's Hospital3
  • Ghent University Hospital3
  • Medical University of Vienna3
  • Amsterdam University Medical Centres2
  • Charles University and Thomayer Hospital2

Disease biology

1 match

Key proteins & gene products studied in this disease. Number shows shared papers.

Related conditions

12 matches

Diseases frequently studied alongside this one. Number shows shared papers.

Disease profile

A grounded synthesis of the condition — overview, causes, mechanism, risk factors and current standard of care.

Overview

Chronic disease refers to a class of illnesses that are long-lasting, may be permanent, and can leave residual disability or require prolonged supervision, observation, or care. In epidemiological use, it often includes conditions such as heart disease, stroke, cancer, and type 2 diabetes mellitus.

Causes

The grounding does not support a single cause or aetiology for chronic disease as a category. It is described as encompassing diseases with persistent or nonreversible pathological alteration rather than having one unified cause.

Pathophysiology

The literature grounding treats chronic disease as a broad category associated with shared biological processes rather than one mechanism. Reported mechanisms across chronic diseases include oxidative stress, chronic inflammation and cytokine signaling, altered signal transduction, aging-related changes, wound healing and tissue remodeling, neuronal plasticity, and matrix metalloproteinase-mediated extracellular matrix turnover.

Risk factors

Supported risk factors in the grounding are broad and mechanism-linked rather than disease-specific. These include psychological stress, diet, lifestyle factors, aging, cigarette smoking, pollution, radiation, certain drugs, and prior child maltreatment as a long-term risk factor for later mental and physical health outcomes.

Current standard of care

The grounding does not support a single standard treatment for chronic disease as a category. It indicates that management is disease-specific and may involve targeted therapies in some chronic inflammatory diseases, along with rehabilitation, long-term supervision, and care.

AI-generated summary grounded in MeSH and 6 peer-reviewed sources. Informational only — not medical advice. Generated 2026-07-07.

Reference

Authoritative identity, definition & identifiers.

Defined in MeSH

Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2).

References & data sources
  • Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
  • Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
  • Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
  • Related entities are derived from literature co-mention (studied together) — associative, not causal.